SCHEMBL6690879

SCHEMBL6690879

COC(=O)c1cccc2c1c1c(O)cc(-c3ccc(Cl)cc3)cc1n2Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.47
TBXA2R P21731 6/20 0.47
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
MAPT P10636 4/20 0.41
ALDH1A1 P00352 2/20 0.41
P2RX7 Q99572 1/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
KDM4E B2RXH2 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
POLB P06746 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PPARG P37231 1/20 0.40
THRB P10828 1/20 0.40
ALOX5 P09917 1/20 0.39
PLA2G2A P14555 1/20 0.39
AR P10275 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6894303 0.96 DRD2 (0.44) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6892182 0.94 DRD2 (0.43) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6897038 0.94 PLA2G2A (0.46) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6694644 0.94 AR (0.45) MAPTALDH1A1GAAPKMKDM4E
SCHEMBL6895281 0.93 FAAH (0.44) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6895138 0.93 HSP90AA1 (0.43) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6890338 0.92 MAPT (0.44) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL27538621 0.92 SLC6A4 (0.43) DRD2TBXA2RSLC6A4SLC6A3MAPT
SCHEMBL6893709 0.92 MAPT (0.47) MAPTALDH1A1GAAPKMPOLB
SCHEMBL6897098 0.91 CYP19A1 (0.44) DRD2TBXA2RSLC6A4SLC6A3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP claimed
EP-0952149-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors LILLY CO ELI (US) 2004-06-09 EP disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
CN-1240210-A Substituted tricyclic compound LILLY CO ELI (US) 2000-01-05 CN disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed